On December 1, 2022, it was announced that Portfolio company Lysatpharma and joint venture Novaxomx will begin research and product development in biosurgical treatment therapies. Lysatpharma, a portfolio company of Xlife Sciences (SIX: XLS), and Novaxomx, a joint-venture of Xlife Sciences and Curasan (a leading global provider of biomaterials for bone and tissue regeneration in dental and orthopedic surgery), signed an exclusive license agreement. Novaxomx has obtained the exclusive rights to use Lysatpharma’s patented “exosome” technology for the research of optimizing biomimetic osteoconductive carrier materials by biologizing them with exosomes.
Login Or Register To Read Full Story